Dibenzepine

Structural formula
General
Non-proprietary name	Dibenzepine
other names	10- [2- (dimethylamino) ethyl] -5-methyl-10,11-dihydro-5 H -dibenzo [ b , e ] [1,4] diazepin-11-one ( IUPAC ); Dibenzepinum ( Latin );
Molecular formula	C 18 H 21 N 3 O
External identifiers / databases
PubChem	9419
Wikidata	Q412107
Drug information
ATC code	N06 AA08
Drug class	Tricyclic antidepressants
Mechanism of action	non-selective monoamine reuptake inhibitor
properties
Molar mass	295.38 g · mol -1
Physical state	firmly
Melting point	116-117 ° C
boiling point	185 ° C (1.3 Pa )
pK s value	8.25 (monohydrochloride)
solubility	soluble in ethanol , chloroform , water (monohydrochloride)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
Toxicological data	194 mg kg −1 ( LD 50 , mouse , oral )
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dibenzepine (manufacturer: Novartis ) is a tricyclic antidepressant that came onto the German market in 1965 . Its chemical structure is related to the benzodiazepines and some neuroleptics ( clozapine , olanzapine , quetiapine , zotepine ), but without sharing their pharmacological properties. Dibenzepine has a relatively short half-life of approx. 9 hours with a plasma binding of 80%. It has a sedative , antidepressant and anxiolytic effect . It has the typical side effects of the tricyclic antidepressants (see there ).

Therapeutically, doses of 240 to 720 mg are used daily. In contrast to other tricyclic antidepressants, toxic plasma levels of dibenzepine are significantly higher (over 3000 ng / ml).

Use in pregnancy

There is clear evidence of risks to the human fetus, but the therapeutic benefits to the mother may outweigh the risks. Dibenzepine should only be used during pregnancy if absolutely necessary.

Effects on ability to drive and use machines

Dibenzepine can reduce responsiveness. This must be taken into account in relation to the ability to drive and use machines.

Trade names

Monopreparations

Noveril TR (CH), Noveril retard (A)

Individual evidence

↑ ^a ^b ^c Entry on dibenzepine. In: Römpp Online . Georg Thieme Verlag, accessed on July 7, 2014.
^ The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, ISBN 978-0-911910-00-1 .
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Entry on dibenzepine in the ChemIDplus database of the United States National Library of Medicine (NLM) .
↑ Psychiatric Drugs Timeline .
↑ ^a ^b ^c ^d Specialist information Noveril ^® TR, Swiss Medicines Compendium, as of June 2010.
↑ Laborlexikon.de .
↑ AGES-PharmMed, as of June 2010.

[RÖMPP_Online-1] Entry on dibenzepine. In: Römpp Online . Georg Thieme Verlag, accessed on July 7, 2014.

[2] The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, ISBN 978-0-911910-00-1 .

[NV-3] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[4] Entry on dibenzepine in the ChemIDplus database of the United States National Library of Medicine (NLM) .

[5] Psychiatric Drugs Timeline .

[Noveril-6] Specialist information Noveril ^® TR, Swiss Medicines Compendium, as of June 2010.

[7] Laborlexikon.de .

[8] AGES-PharmMed, as of June 2010.